HC Wainwright Reaffirms Buy Rating for Longeveron (NASDAQ:LGVN)

Longeveron (NASDAQ:LGVN)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research report issued on Monday,Benzinga reports. They currently have a $10.00 price objective on the stock.

Other equities research analysts also recently issued reports about the company. Roth Capital raised Longeveron to a “strong-buy” rating in a research report on Thursday, December 5th. Roth Mkm began coverage on Longeveron in a research report on Friday, December 6th. They set a “buy” rating and a $10.00 target price on the stock.

Longeveron Stock Performance

Shares of NASDAQ:LGVN opened at $1.33 on Monday. The company has a market cap of $19.73 million, a P/E ratio of -0.21 and a beta of 0.36. The stock’s 50-day moving average is $1.65 and its 200-day moving average is $1.90. Longeveron has a 52-week low of $0.77 and a 52-week high of $6.40.

Institutional Investors Weigh In On Longeveron

A number of institutional investors have recently added to or reduced their stakes in LGVN. Geode Capital Management LLC grew its position in Longeveron by 316.0% during the third quarter. Geode Capital Management LLC now owns 128,947 shares of the company’s stock worth $250,000 after buying an additional 97,953 shares in the last quarter. Virtu Financial LLC acquired a new stake in Longeveron during the fourth quarter valued at approximately $53,000. Jane Street Group LLC acquired a new stake in Longeveron during the fourth quarter valued at approximately $35,000. Northern Trust Corp acquired a new stake in Longeveron during the fourth quarter valued at approximately $31,000. Finally, State Street Corp acquired a new stake in Longeveron during the third quarter valued at approximately $29,000. 10.01% of the stock is owned by institutional investors and hedge funds.

About Longeveron

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.